<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 15 Dec 2024 03:02:55 +0000</lastbuilddate>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>A rare aortic pseudoaneurysm-right atrial fistula</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673760/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae860. doi: 10.1093/eurheartj/ehae860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673760/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673760</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae860>10.1093/eurheartj/ehae860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673760</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yankai Mao</dc:creator>
<dc:creator>Jiwen Li</dc:creator>
<dc:creator>Jie Han</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A rare aortic pseudoaneurysm-right atrial fistula</dc:title>
<dc:identifier>pmid:39673760</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae860</dc:identifier>
</item>
<item>
<title>Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673759/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae744. doi: 10.1093/eurheartj/ehae744. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673759/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673759</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae744>10.1093/eurheartj/ehae744</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673759</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Francesco Cosentino</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide</dc:title>
<dc:identifier>pmid:39673759</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae744</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: The jury is still out on beta-blockers following acute myocardial infarction with preserved ejection fraction after the ABYSS trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673758/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae858. doi: 10.1093/eurheartj/ehae858. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673758/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673758</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae858>10.1093/eurheartj/ehae858</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673758</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: The jury is still out on beta-blockers following acute myocardial infarction with preserved ejection fraction after the ABYSS trial</dc:title>
<dc:identifier>pmid:39673758</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae858</dc:identifier>
</item>
<item>
<title>Connecting the dots: the Mediterranean diet, neutrophil count, and atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae799. doi: 10.1093/eurheartj/ehae799. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673756</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae799>10.1093/eurheartj/ehae799</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673756</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Marta Guasch-Ferré</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Connecting the dots: the Mediterranean diet, neutrophil count, and atherosclerosis</dc:title>
<dc:identifier>pmid:39673756</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae799</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: HELIOS-B sheds light on new therapeutic options for transthyretin amyloidosis with cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673755/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 14:ehae838. doi: 10.1093/eurheartj/ehae838. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673755/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673755</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae838>10.1093/eurheartj/ehae838</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673755</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: HELIOS-B sheds light on new therapeutic options for transthyretin amyloidosis with cardiomyopathy</dc:title>
<dc:identifier>pmid:39673755</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae838</dc:identifier>
</item>
<item>
<title>Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>In the modern era, cardiologists managing patients and families with cardiomyopathies need to be familiar with every stage of the diagnostic pathway from clinical phenotyping to the prescription and interpretation of genetic tests. This clinical consensus statement from the ESC Council for Cardiovascular Genomics aims to promote the integration of genetic testing into routine cardiac care of patients with cardiomyopathies, as recommended in the 2023 ESC guidelines for cardiomyopathies. The...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 3:ehae747. doi: 10.1093/eurheartj/ehae747. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In the modern era, cardiologists managing patients and families with cardiomyopathies need to be familiar with every stage of the diagnostic pathway from clinical phenotyping to the prescription and interpretation of genetic tests. This clinical consensus statement from the ESC Council for Cardiovascular Genomics aims to promote the integration of genetic testing into routine cardiac care of patients with cardiomyopathies, as recommended in the 2023 ESC guidelines for cardiomyopathies. The document describes the types of genetic tests currently available and provides advice on their prescription and for counselling after the return of genetic findings, including the approach in patients and families with variants of unknown significance.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673718</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae747>10.1093/eurheartj/ehae747</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673718</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Antoine Bondue</dc:creator>
<dc:creator>Elijah Behr</dc:creator>
<dc:creator>Lucie Carrier</dc:creator>
<dc:creator>Cornelia Van Duijn</dc:creator>
<dc:creator>Pablo García-Pavía</dc:creator>
<dc:creator>Pim van der Harst</dc:creator>
<dc:creator>Maryam Kavousi</dc:creator>
<dc:creator>Bart Loeys</dc:creator>
<dc:creator>Luis Rocha Lopes</dc:creator>
<dc:creator>Yigal Pinto</dc:creator>
<dc:creator>Alessandro Di Toro</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:creator>Stefan Kääb</dc:creator>
<dc:creator>Mario Urtis</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Integration of genetic testing into diagnostic pathways for cardiomyopathies: a clinical consensus statement by the ESC Council on Cardiovascular Genomics</dc:title>
<dc:identifier>pmid:39673718</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae747</dc:identifier>
</item>
<item>
<title>Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>Haemostasis refers to the physiological process aimed at repairing vessel injury and preventing bleeding. It involves four interlinked stages culminating in the formation of a platelet-fibrin haemostatic plug that is eventually dissolved once the vessel heals. In contrast, arterial thrombosis is a pathological condition resulting from atheroma exposure, triggering the formation of a platelet-rich thrombus that may obstruct blood flow, leading to the clinical manifestations of ischaemic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 3:ehae776. doi: 10.1093/eurheartj/ehae776. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Haemostasis refers to the physiological process aimed at repairing vessel injury and preventing bleeding. It involves four interlinked stages culminating in the formation of a platelet-fibrin haemostatic plug that is eventually dissolved once the vessel heals. In contrast, arterial thrombosis is a pathological condition resulting from atheroma exposure, triggering the formation of a platelet-rich thrombus that may obstruct blood flow, leading to the clinical manifestations of ischaemic cardiovascular disease. The following review will provide a comprehensive overview of the finely regulated endogenous antithrombotic mechanisms responsible for maintaining the haemostatic balance and preventing intravascular thrombosis. Thereafter, it will further detail the different stages and mechanisms governing the intricate interplay between the vessel, platelets, and the coagulation cascade in haemostasis, highlighting the most recent advances in platelet biology and function, to further elucidate the differential traits and players contributing to pathological arterial thrombus growth. The review will also delve into the impact of emerging cardiovascular risk factors on tilting the haemostatic balance towards a pro-thrombotic state, thereby increasing the patient's vulnerability to thrombotic events. Finally, it will underscore the importance of early screening for subclinical atherosclerosis through advanced imaging technologies capable of quantifying plaque burden and metabolic activity since they may set the stage for an increased thrombotic risk. Implementing proactive interventions to halt atherosclerosis progression or inducing its regression at early stages is crucial for preserving haemostasis and reducing the likelihood of ischaemic atherothrombotic disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673717</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae776>10.1093/eurheartj/ehae776</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673717</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis</dc:title>
<dc:identifier>pmid:39673717</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae776</dc:identifier>
</item>
<item>
<title>Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39673349/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Overexpressing Gata4 in CFs may be a promising therapeutic approach for HFpEF by suppressing fibrosis and improving diastolic dysfunction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Dec 14. doi: 10.1161/CIRCULATIONAHA.123.067504. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to cardiac fibrosis and diastolic dysfunction, which are hallmarks of HFpEF. Interstitial and perivascular cardiac fibrosis correlates with poor prognosis in HFpEF; however, mechanisms of fibrosis remain poorly elucidated, and targeted therapies are lacking. Cardiac reprogramming is a promising therapeutic approach for myocardial infarction that facilitates cardiac regeneration and antifibrosis action through <i>Mef2c/Gata4/Tbx5/Hand2</i> (MGTH) overexpression in resident CFs. However, the efficacy of this approach on HFpEF is yet to be established.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Herein, we examined the effects of cardiac reprogramming in HFpEF using Tcf21<sup>iCre</sup>/Tomato/MGTH2A transgenic mice, which expressed both MGTH and reporter expression in CFs for cardiac reprogramming and lineage tracing upon tamoxifen administration. To establish HFpEF model mice, we used a combination of a high-fat diet and nitric oxide synthase inhibition. Bulk RNA-sequencing, single-cell RNA-sequencing, and spatial transcriptomics were conducted to determine fibrotic mechanisms and the efficacy of cardiac reprogramming in HFpEF. We generated new tamoxifen-inducible transgenic mice overexpressing each reprogramming factor in CFs to investigate the effect of single factors. Last, we analyzed the effect of reprogramming factors in human CFs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cardiac reprogramming with MGTH overexpression improved diastolic dysfunction, cardiac hypertrophy, fibrosis, inflammation, and capillary loss in HFpEF. Cardiac reprogramming converted approximately 1% of resident CFs into induced cardiomyocytes. Bulk RNA-seq indicated that MGTH overexpression upregulated genes related to heart contraction and suppressed the fetal gene program (<i>Nppa</i> and <i>Nppb</i>) and proinflammatory and fibrotic signatures. Single-cell RNA-sequencing and spatial transcriptomics revealed that multiple CF clusters upregulated fibrotic genes to induce diffuse interstitial fibrosis, whereas distinct CF clusters generated focal perivascular fibrosis in HFpEF. MGTH overexpression reversed these profibrotic changes. Among 4 reprogramming factors, only Gata4 overexpression in CFs reduced fibrosis and improved diastolic dysfunction in HFpEF by suppressing CF activation without generating new induced cardiomyocytes. Gata4 overexpression also suppressed profibrotic signatures in human CFs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Overexpressing Gata4 in CFs may be a promising therapeutic approach for HFpEF by suppressing fibrosis and improving diastolic dysfunction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39673349/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39673349</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067504>10.1161/CIRCULATIONAHA.123.067504</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39673349</guid>
<pubDate>Sat, 14 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yu Yamada</dc:creator>
<dc:creator>Taketaro Sadahiro</dc:creator>
<dc:creator>Koji Nakano</dc:creator>
<dc:creator>Seiichiro Honda</dc:creator>
<dc:creator>Yuto Abe</dc:creator>
<dc:creator>Tatsuya Akiyama</dc:creator>
<dc:creator>Ryo Fujita</dc:creator>
<dc:creator>Masashi Nakamura</dc:creator>
<dc:creator>Takashi Maeda</dc:creator>
<dc:creator>Yuta Kuze</dc:creator>
<dc:creator>Masaya Onishi</dc:creator>
<dc:creator>Masahide Seki</dc:creator>
<dc:creator>Yutaka Suzuki</dc:creator>
<dc:creator>Chikara Takeuchi</dc:creator>
<dc:creator>Yuka W Iwasaki</dc:creator>
<dc:creator>Kensaku Murano</dc:creator>
<dc:creator>Mamiko Sakata-Yanagimoto</dc:creator>
<dc:creator>Shigeru Chiba</dc:creator>
<dc:creator>Hideyuki Kato</dc:creator>
<dc:creator>Hiroaki Sakamoto</dc:creator>
<dc:creator>Yuji Hiramatsu</dc:creator>
<dc:creator>Masaki Ieda</dc:creator>
<dc:date>2024-12-14</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39673349</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067504</dc:identifier>
</item>
<item>
<title>Understanding ezetimibe's role in lipid lowering and its limited impact on venous thromboembolism risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39672597/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 13:ehae857. doi: 10.1093/eurheartj/ehae857. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39672597/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39672597</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae857>10.1093/eurheartj/ehae857</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39672597</guid>
<pubDate>Fri, 13 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Ioannis T Farmakis</dc:creator>
<dc:creator>Stavros V Konstantinides</dc:creator>
<dc:creator>Luca Valerio</dc:creator>
<dc:date>2024-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Understanding ezetimibe's role in lipid lowering and its limited impact on venous thromboembolism risk</dc:title>
<dc:identifier>pmid:39672597</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae857</dc:identifier>
</item>
<item>
<title>Why couldn't lipid-lowering therapies of ezetimibe combined with statin further reduce the risk of venous thromboembolism?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39672565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Dec 13:ehae856. doi: 10.1093/eurheartj/ehae856. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39672565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39672565</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae856>10.1093/eurheartj/ehae856</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39672565</guid>
<pubDate>Fri, 13 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Lingyan Lv</dc:creator>
<dc:date>2024-12-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Why couldn't lipid-lowering therapies of ezetimibe combined with statin further reduce the risk of venous thromboembolism?</dc:title>
<dc:identifier>pmid:39672565</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae856</dc:identifier>
</item>
<item>
<title>Regulation of human interferon signaling by transposon exonization</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39672162/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>Innate immune signaling is essential for clearing pathogens and damaged cells and must be tightly regulated to avoid excessive inflammation or autoimmunity. Here, we found that the alternative splicing of exons derived from transposable elements is a key mechanism controlling immune signaling in human cells. By analyzing long-read transcriptome datasets, we identified numerous transposon exonization events predicted to generate functional protein variants of immune genes, including the type I...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 10:S0092-8674(24)01333-3. doi: 10.1016/j.cell.2024.11.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Innate immune signaling is essential for clearing pathogens and damaged cells and must be tightly regulated to avoid excessive inflammation or autoimmunity. Here, we found that the alternative splicing of exons derived from transposable elements is a key mechanism controlling immune signaling in human cells. By analyzing long-read transcriptome datasets, we identified numerous transposon exonization events predicted to generate functional protein variants of immune genes, including the type I interferon receptor IFNAR2. We demonstrated that the transposon-derived isoform of IFNAR2 is more highly expressed than the canonical isoform in almost all tissues and functions as a decoy receptor that potently inhibits interferon signaling, including in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our findings uncover a primate-specific axis controlling interferon signaling and show how a transposon exonization event can be co-opted for immune regulation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39672162/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39672162</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.016>10.1016/j.cell.2024.11.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39672162</guid>
<pubDate>Fri, 13 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Giulia Irene Maria Pasquesi</dc:creator>
<dc:creator>Holly Allen</dc:creator>
<dc:creator>Atma Ivancevic</dc:creator>
<dc:creator>Arturo Barbachano-Guerrero</dc:creator>
<dc:creator>Olivia Joyner</dc:creator>
<dc:creator>Kejun Guo</dc:creator>
<dc:creator>David M Simpson</dc:creator>
<dc:creator>Keala Gapin</dc:creator>
<dc:creator>Isabella Horton</dc:creator>
<dc:creator>Lily L Nguyen</dc:creator>
<dc:creator>Qing Yang</dc:creator>
<dc:creator>Cody J Warren</dc:creator>
<dc:creator>Liliana D Florea</dc:creator>
<dc:creator>Benjamin G Bitler</dc:creator>
<dc:creator>Mario L Santiago</dc:creator>
<dc:creator>Sara L Sawyer</dc:creator>
<dc:creator>Edward B Chuong</dc:creator>
<dc:date>2024-12-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Regulation of human interferon signaling by transposon exonization</dc:title>
<dc:identifier>pmid:39672162</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.016</dc:identifier>
</item>
<item>
<title>Keiji Tanaka (1949-2024)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39672100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 12;187(25):7064-7065. doi: 10.1016/j.cell.2024.11.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39672100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39672100</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.019>10.1016/j.cell.2024.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39672100</guid>
<pubDate>Fri, 13 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Shigeo Murata</dc:creator>
<dc:creator>Kazuhiro Iwai</dc:creator>
<dc:date>2024-12-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Keiji Tanaka (1949-2024)</dc:title>
<dc:identifier>pmid:39672100</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.019</dc:identifier>
</item>
<item>
<title>How to build the virtual cell with artificial intelligence: Priorities and opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39672099/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>Cells are essential to understanding health and disease, yet traditional models fall short of modeling and simulating their function and behavior. Advances in AI and omics offer groundbreaking opportunities to create an AI virtual cell (AIVC), a multi-scale, multi-modal large-neural-network-based model that can represent and simulate the behavior of molecules, cells, and tissues across diverse states. This Perspective provides a vision on their design and how collaborative efforts to build AIVCs...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 12;187(25):7045-7063. doi: 10.1016/j.cell.2024.11.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cells are essential to understanding health and disease, yet traditional models fall short of modeling and simulating their function and behavior. Advances in AI and omics offer groundbreaking opportunities to create an AI virtual cell (AIVC), a multi-scale, multi-modal large-neural-network-based model that can represent and simulate the behavior of molecules, cells, and tissues across diverse states. This Perspective provides a vision on their design and how collaborative efforts to build AIVCs will transform biological research by allowing high-fidelity simulations, accelerating discoveries, and guiding experimental studies, offering new opportunities for understanding cellular functions and fostering interdisciplinary collaborations in open science.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39672099/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39672099</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.015>10.1016/j.cell.2024.11.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39672099</guid>
<pubDate>Fri, 13 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Charlotte Bunne</dc:creator>
<dc:creator>Yusuf Roohani</dc:creator>
<dc:creator>Yanay Rosen</dc:creator>
<dc:creator>Ankit Gupta</dc:creator>
<dc:creator>Xikun Zhang</dc:creator>
<dc:creator>Marcel Roed</dc:creator>
<dc:creator>Theo Alexandrov</dc:creator>
<dc:creator>Mohammed AlQuraishi</dc:creator>
<dc:creator>Patricia Brennan</dc:creator>
<dc:creator>Daniel B Burkhardt</dc:creator>
<dc:creator>Andrea Califano</dc:creator>
<dc:creator>Jonah Cool</dc:creator>
<dc:creator>Abby F Dernburg</dc:creator>
<dc:creator>Kirsty Ewing</dc:creator>
<dc:creator>Emily B Fox</dc:creator>
<dc:creator>Matthias Haury</dc:creator>
<dc:creator>Amy E Herr</dc:creator>
<dc:creator>Eric Horvitz</dc:creator>
<dc:creator>Patrick D Hsu</dc:creator>
<dc:creator>Viren Jain</dc:creator>
<dc:creator>Gregory R Johnson</dc:creator>
<dc:creator>Thomas Kalil</dc:creator>
<dc:creator>David R Kelley</dc:creator>
<dc:creator>Shana O Kelley</dc:creator>
<dc:creator>Anna Kreshuk</dc:creator>
<dc:creator>Tim Mitchison</dc:creator>
<dc:creator>Stephani Otte</dc:creator>
<dc:creator>Jay Shendure</dc:creator>
<dc:creator>Nicholas J Sofroniew</dc:creator>
<dc:creator>Fabian Theis</dc:creator>
<dc:creator>Christina V Theodoris</dc:creator>
<dc:creator>Srigokul Upadhyayula</dc:creator>
<dc:creator>Marc Valer</dc:creator>
<dc:creator>Bo Wang</dc:creator>
<dc:creator>Eric Xing</dc:creator>
<dc:creator>Serena Yeung-Levy</dc:creator>
<dc:creator>Marinka Zitnik</dc:creator>
<dc:creator>Theofanis Karaletsos</dc:creator>
<dc:creator>Aviv Regev</dc:creator>
<dc:creator>Emma Lundberg</dc:creator>
<dc:creator>Jure Leskovec</dc:creator>
<dc:creator>Stephen R Quake</dc:creator>
<dc:date>2024-12-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>How to build the virtual cell with artificial intelligence: Priorities and opportunities</dc:title>
<dc:identifier>pmid:39672099</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.015</dc:identifier>
</item>
<item>
<title>Human hippocampal CA3 uses specific functional connectivity rules for efficient associative memory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39667938/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>Our brain has remarkable computational power, generating sophisticated behaviors, storing memories over an individual's lifetime, and producing higher cognitive functions. However, little of our neuroscience knowledge covers the human brain. Is this organ truly unique, or is it a scaled version of the extensively studied rodent brain? Combining multicellular patch-clamp recording with expansion-based superresolution microscopy and full-scale modeling, we determined the cellular and microcircuit...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 6:S0092-8674(24)01338-2. doi: 10.1016/j.cell.2024.11.022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Our brain has remarkable computational power, generating sophisticated behaviors, storing memories over an individual's lifetime, and producing higher cognitive functions. However, little of our neuroscience knowledge covers the human brain. Is this organ truly unique, or is it a scaled version of the extensively studied rodent brain? Combining multicellular patch-clamp recording with expansion-based superresolution microscopy and full-scale modeling, we determined the cellular and microcircuit properties of the human hippocampal CA3 region, a fundamental circuit for memory storage. In contrast to neocortical networks, human hippocampal CA3 displayed sparse connectivity, providing a circuit architecture that maximizes associational power. Human synapses showed unique reliability, high precision, and long integration times, exhibiting both species- and circuit-specific properties. Together with expanded neuronal numbers, these circuit characteristics greatly enhanced the memory storage capacity of CA3. Our results reveal distinct microcircuit properties of the human hippocampus and begin to unravel the inner workings of our most complex organ.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39667938/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39667938</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.022>10.1016/j.cell.2024.11.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39667938</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jake F Watson</dc:creator>
<dc:creator>Victor Vargas-Barroso</dc:creator>
<dc:creator>Rebecca J Morse-Mora</dc:creator>
<dc:creator>Andrea Navas-Olive</dc:creator>
<dc:creator>Mojtaba R Tavakoli</dc:creator>
<dc:creator>Johann G Danzl</dc:creator>
<dc:creator>Matthias Tomschik</dc:creator>
<dc:creator>Karl Rössler</dc:creator>
<dc:creator>Peter Jonas</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Human hippocampal CA3 uses specific functional connectivity rules for efficient associative memory</dc:title>
<dc:identifier>pmid:39667938</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.022</dc:identifier>
</item>
<item>
<title>Transposable element exonization generates a reservoir of evolving and functional protein isoforms</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39667937/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>Alternative splicing enhances protein diversity in different ways, including through exonization of transposable elements (TEs). Recent transcriptomic analyses identified thousands of unannotated spliced transcripts with exonizing TEs, but their contribution to the proteome and biological relevance remains unclear. Here, we use transcriptome assembly, ribosome profiling, and proteomics to describe a population of 1,227 unannotated TE exonizing isoforms generated by mRNA splicing and recurrent in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 9:S0092-8674(24)01328-X. doi: 10.1016/j.cell.2024.11.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Alternative splicing enhances protein diversity in different ways, including through exonization of transposable elements (TEs). Recent transcriptomic analyses identified thousands of unannotated spliced transcripts with exonizing TEs, but their contribution to the proteome and biological relevance remains unclear. Here, we use transcriptome assembly, ribosome profiling, and proteomics to describe a population of 1,227 unannotated TE exonizing isoforms generated by mRNA splicing and recurrent in human populations. Despite being shorter and lowly expressed, these isoforms are shared between individuals and efficiently translated. Functional analyses show stable expression, specific cellular localization, and, in some cases, modified functions. Exonized TEs are rich in ancient genes, whereas the involved splice sites are recent and can be evolutionarily conserved. In addition, exonized TEs contribute to the secondary structure of the emerging isoforms, supporting their functional relevance. We conclude that TE-spliced isoforms represent a diversity reservoir of functional proteins on which natural selection can act.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39667937/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39667937</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.011>10.1016/j.cell.2024.11.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39667937</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Yago A Arribas</dc:creator>
<dc:creator>Blandine Baudon</dc:creator>
<dc:creator>Maxime Rotival</dc:creator>
<dc:creator>Guadalupe Suárez</dc:creator>
<dc:creator>Pierre-Emmanuel Bonté</dc:creator>
<dc:creator>Vanessa Casas</dc:creator>
<dc:creator>Apollinaire Roubert</dc:creator>
<dc:creator>Paul Klein</dc:creator>
<dc:creator>Elisa Bonnin</dc:creator>
<dc:creator>Basma Mchich</dc:creator>
<dc:creator>Patricia Legoix</dc:creator>
<dc:creator>Sylvain Baulande</dc:creator>
<dc:creator>Benjamin Sadacca</dc:creator>
<dc:creator>Julien Diharce</dc:creator>
<dc:creator>Joshua J Waterfall</dc:creator>
<dc:creator>Catherine Etchebest</dc:creator>
<dc:creator>Montserrat Carrascal</dc:creator>
<dc:creator>Christel Goudot</dc:creator>
<dc:creator>Lluís Quintana-Murci</dc:creator>
<dc:creator>Marianne Burbage</dc:creator>
<dc:creator>Antonela Merlotti</dc:creator>
<dc:creator>Sebastian Amigorena</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Transposable element exonization generates a reservoir of evolving and functional protein isoforms</dc:title>
<dc:identifier>pmid:39667937</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.011</dc:identifier>
</item>
<item>
<title>How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39667936/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>Ninjurin-1 (NINJ1) is an active executioner of plasma membrane rupture (PMR), a process previously thought to be a passive osmotic lysis event in lytic cell death. Ninjurin-2 (NINJ2) is a close paralog of NINJ1 but cannot mediate PMR. Using cryogenic electron microscopy (cryo-EM), we show that NINJ1 and NINJ2 both assemble into linear filaments that are hydrophobic on one side but hydrophilic on the other. This structural feature and other evidence point to a PMR mechanism by which NINJ1...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 3:S0092-8674(24)01337-0. doi: 10.1016/j.cell.2024.11.021. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ninjurin-1 (NINJ1) is an active executioner of plasma membrane rupture (PMR), a process previously thought to be a passive osmotic lysis event in lytic cell death. Ninjurin-2 (NINJ2) is a close paralog of NINJ1 but cannot mediate PMR. Using cryogenic electron microscopy (cryo-EM), we show that NINJ1 and NINJ2 both assemble into linear filaments that are hydrophobic on one side but hydrophilic on the other. This structural feature and other evidence point to a PMR mechanism by which NINJ1 filaments wrap around and solubilize membrane fragments and, less frequently, form pores in the plasma membrane. In contrast to the straight NINJ1 filament, the NINJ2 filament is curved toward the intracellular space, preventing its circularization or even assembly on a relatively flat membrane to mediate PMR. Mutagenesis studies further demonstrate that the NINJ2 filament curvature is induced by strong association with lipids, particularly a cholesterol molecule, at the cytoplasmic leaflet of the lipid bilayer.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39667936/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39667936</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.021>10.1016/j.cell.2024.11.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39667936</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Bibekananda Sahoo</dc:creator>
<dc:creator>Zongjun Mou</dc:creator>
<dc:creator>Wei Liu</dc:creator>
<dc:creator>George Dubyak</dc:creator>
<dc:creator>Xinghong Dai</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot</dc:title>
<dc:identifier>pmid:39667936</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.021</dc:identifier>
</item>
<item>
<title>Rheumatic Valve Surgery in Sudan: Results in 7,449 Patients at the Salam Centre for Cardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39665704/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 3:S0735-1097(24)10032-0. doi: 10.1016/j.jacc.2024.09.1232. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39665704/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39665704</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1232>10.1016/j.jacc.2024.09.1232</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39665704</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Gina Portella</dc:creator>
<dc:creator>Liliane Chatenoud</dc:creator>
<dc:creator>Sofia Gatti</dc:creator>
<dc:creator>Alessandro C Salvati</dc:creator>
<dc:creator>Lino Asta</dc:creator>
<dc:creator>Salvatore Lentini</dc:creator>
<dc:creator>Juha Puntila</dc:creator>
<dc:creator>Franco Masini</dc:creator>
<dc:creator>Sofia Redaelli</dc:creator>
<dc:creator>Alessandro Mocini</dc:creator>
<dc:creator>Suha Abdelwahab Abdallah</dc:creator>
<dc:creator>Sohayda Hussein Abdalla Abdalla</dc:creator>
<dc:creator>Nicoletta Erba</dc:creator>
<dc:creator>Elena Giovanella</dc:creator>
<dc:creator>Dimiana Raafat Shafig Saber</dc:creator>
<dc:creator>Daniela Rocchi</dc:creator>
<dc:creator>Manahel Badr Saad</dc:creator>
<dc:creator>Lorenzo Valgoi</dc:creator>
<dc:creator>Paolo Malerba</dc:creator>
<dc:creator>Luca Rolla</dc:creator>
<dc:creator>Antonio Pesenti</dc:creator>
<dc:creator>Roberto Latini</dc:creator>
<dc:creator>Pietro Parrino</dc:creator>
<dc:creator>Rossella Miccio</dc:creator>
<dc:creator>Martin Langer</dc:creator>
<dc:creator>Salam Centre Working Group</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rheumatic Valve Surgery in Sudan: Results in 7,449 Patients at the Salam Centre for Cardiac Surgery</dc:title>
<dc:identifier>pmid:39665704</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1232</dc:identifier>
</item>
<item>
<title>2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39665703/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 4:S0735-1097(24)10040-X. doi: 10.1016/j.jacc.2024.10.080. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39665703/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39665703</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.080>10.1016/j.jacc.2024.10.080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39665703</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Writing Committee</dc:creator>
<dc:creator>Mark H Drazner</dc:creator>
<dc:creator>Biykem Bozkurt</dc:creator>
<dc:creator>Leslie T Cooper</dc:creator>
<dc:creator>Niti R Aggarwal</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Nicole M Bhave</dc:creator>
<dc:creator>Alida L P Caforio</dc:creator>
<dc:creator>Vanessa M Ferreira</dc:creator>
<dc:creator>Bettina Heidecker</dc:creator>
<dc:creator>Amy R Kontorovich</dc:creator>
<dc:creator>Pilar Martín</dc:creator>
<dc:creator>Gregory A Roth</dc:creator>
<dc:creator>Jennifer E Van Eyk</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee</dc:title>
<dc:identifier>pmid:39665703</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.080</dc:identifier>
</item>
<item>
<title>Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39665702/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 4:S0735-1097(24)10043-5. doi: 10.1016/j.jacc.2024.10.081. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39665702/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39665702</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.081>10.1016/j.jacc.2024.10.081</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39665702</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Prakriti Gaba</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Thorsten M Leucker</dc:creator>
<dc:creator>Julia F Kuder</dc:creator>
<dc:creator>KyungAh Im</dc:creator>
<dc:creator>Helina Kassahun</dc:creator>
<dc:creator>Huei Wang</dc:creator>
<dc:creator>You Wu</dc:creator>
<dc:creator>Jingying Wang</dc:creator>
<dc:creator>E Magnus Ohman</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial</dc:title>
<dc:identifier>pmid:39665702</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.081</dc:identifier>
</item>
<item>
<title>Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39665701/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients with HF with mildly reduced/preserved ejection fraction, the beneficial effects of finerenone on clinical events and symptoms were consistent, irrespective of BMI at baseline, possibly with a greater effect on the primary outcome in patients with higher BMI. (FINEARTS-HF [FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure]; NCT04435626).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 4:S0735-1097(24)10423-8. doi: 10.1016/j.jacc.2024.10.111. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin-angiotensin-aldosterone cascade, and mineralocorticoid receptor antagonists may be more effective in patients with heart failure (HF) and obesity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to examine the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone compared with placebo, according to body mass index (BMI) in FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 6,001 patients with HF with NYHA functional class II, III, and IV, a left ventricular ejection fraction of ≥40%, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized to finerenone or placebo. BMI (kg/m<sup>2</sup>) was examined using World Health Organization categories, namely, underweight/normal weight (&lt;25.0 kg/m<sup>2</sup>; n = 1,306); overweight (25.0-29.9 kg/m<sup>2</sup>; n = 1,990); obesity class I (30.0-34.9 kg/m<sup>2</sup>; n = 1,546); obesity class II (35.0-39.9 kg/m<sup>2</sup>; n = 751); and obesity class III (≥40 kg/m<sup>2</sup>; n = 395). The primary outcome was cardiovascular death and total worsening HF events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Data on baseline BMI were available for 5,988 patients (median: 29.2 kg/m<sup>2</sup>; Q1-Q3: 25.5-33.6 kg/m<sup>2</sup>). Compared with patients who were underweight/normal weight, those with obesity class II or III had a higher risk of the primary outcome (underweight/normal weight, reference; overweight, unadjusted rate ratio: 0.96 [95% CI: 0.81-1.15]; obesity class I: 1.04 [95% CI: 0.86-1.26]; obesity class II-III: 1.26 [95% CI: 1.03-1.54]). The effect of finerenone on the primary outcome did not vary by baseline BMI (underweight/normal weight, rate ratio: 0.80 [95% CI: 0.62-1.04]; overweight: 0.91 [95% CI: 0.72-1.15]; obesity class I: 0.92 [95% CI: 0.72-1.19]; obesity class II-III: 0.67 [95% CI: 0.50-0.89]; P<sub>interaction</sub> = 0.32). However, when BMI was examined as a continuous variable, the beneficial effect of finerenone seemed to be greater in those with a higher BMI (P<sub>interaction</sub> = 0.005). A similar pattern was observed for total worsening HF events. Consistent effects across baseline BMI were observed for cardiovascular and all-cause death and improvement in the Kansas City Cardiomyopathy Questionnaire scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with HF with mildly reduced/preserved ejection fraction, the beneficial effects of finerenone on clinical events and symptoms were consistent, irrespective of BMI at baseline, possibly with a greater effect on the primary outcome in patients with higher BMI. (FINEARTS-HF [FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure]; NCT04435626).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39665701/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39665701</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.111>10.1016/j.jacc.2024.10.111</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39665701</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Jawad H Butt</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Andrea Lage</dc:creator>
<dc:creator>Markus F Scheerer</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Cândida Fonseca</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Gerard C M Linssen</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Subodh Verma</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: Prespecified Analysis of FINEARTS-HF</dc:title>
<dc:identifier>pmid:39665701</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.111</dc:identifier>
</item>
<item>
<title>Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry)</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39665700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241214220255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 4:S0735-1097(24)10318-X. doi: 10.1016/j.jacc.2024.10.106. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39665700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241214220255&v=2.18.0.post9+e462414">39665700</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.106>10.1016/j.jacc.2024.10.106</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39665700</guid>
<pubDate>Thu, 12 Dec 2024 06:00:00 -0500</pubDate>
<dc:creator>Paola Gargiulo</dc:creator>
<dc:creator>Federica Marzano</dc:creator>
<dc:creator>Mario Crisci</dc:creator>
<dc:creator>Rossella Marcucci</dc:creator>
<dc:creator>Dario Bruzzese</dc:creator>
<dc:creator>Alessandro Maloberti</dc:creator>
<dc:creator>Filippo Maria Sarullo</dc:creator>
<dc:creator>Gennaro Galasso</dc:creator>
<dc:creator>Ciro Indolfi</dc:creator>
<dc:creator>Giuseppe Musumeci</dc:creator>
<dc:creator>Antonella Corleto</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Stefano Carugo</dc:creator>
<dc:creator>Gavino Casu</dc:creator>
<dc:creator>Amedeo Picciolo</dc:creator>
<dc:creator>Marco Matteo Ciccone</dc:creator>
<dc:creator>Claudio Bilato</dc:creator>
<dc:creator>Alberto Polimeni</dc:creator>
<dc:creator>Francesco Giallauria</dc:creator>
<dc:creator>Angelo Catalano</dc:creator>
<dc:creator>Leonardo De Luca</dc:creator>
<dc:creator>Giampaolo Niccoli</dc:creator>
<dc:creator>Elio Venturini</dc:creator>
<dc:creator>Marco Pepe</dc:creator>
<dc:creator>Roberta Montisci</dc:creator>
<dc:creator>Natale Daniele Brunetti</dc:creator>
<dc:creator>Giuseppe Patti</dc:creator>
<dc:creator>Italo Porto</dc:creator>
<dc:creator>Alberto Margonato</dc:creator>
<dc:creator>Marina Floresta</dc:creator>
<dc:creator>Saverio Muscoli</dc:creator>
<dc:creator>Matteo Cameli</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>Emilio Di Lorenzo</dc:creator>
<dc:creator>Martina Berteotti</dc:creator>
<dc:creator>Cristina Giannattasio</dc:creator>
<dc:creator>Silvia Sarullo</dc:creator>
<dc:creator>Ciro Formisano</dc:creator>
<dc:creator>Assunta Di Costanzo</dc:creator>
<dc:creator>Fabrizio Delnevo</dc:creator>
<dc:creator>Ferdinando Varbella</dc:creator>
<dc:creator>Arturo Cesaro</dc:creator>
<dc:creator>Monica Franzese</dc:creator>
<dc:creator>Costantino Mancusi</dc:creator>
<dc:creator>Sara Fontanarosa</dc:creator>
<dc:creator>Mariafrancesca Di Santo</dc:creator>
<dc:creator>Ciro Cotticelli</dc:creator>
<dc:creator>Fabrizio Perrone Filardi</dc:creator>
<dc:creator>Stefania Paolillo</dc:creator>
<dc:creator>Giovanni Esposito</dc:creator>
<dc:creator>Alberto Corsini</dc:creator>
<dc:creator>Pasquale Perrone Filardi</dc:creator>
<dc:creator>CHOLINET Investigators</dc:creator>
<dc:date>2024-12-12</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry)</dc:title>
<dc:identifier>pmid:39665700</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.106</dc:identifier>
</item>





























</channel>
</rss>